Patents Examined by Peter J. Reddig
  • Patent number: 11446378
    Abstract: Disclosed herein are compositions and methods for tumor treatment involving administering to a subject having a tumor with an amount effective to limit tumor growth or metastasis of an ephrin B1 inhibitor, or a pharmaceutically acceptable salt thereof; and/or an inhibitor of tumor exosomal release, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 20, 2022
    Assignee: Sanford Health
    Inventor: Paola Vermeer
  • Patent number: 11447564
    Abstract: The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: September 20, 2022
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Pengbo Zhang, Yiyang Xu, Javier Morales, Yoko Nakano, Hong Liu, Jingyi Xiang, Timothy Acker
  • Patent number: 11440941
    Abstract: A cancer killer cell in which a therapeutic recombinant protein or recombinant protein which improves cytotoxic activity of the cancer killer cell is loaded. In addition, a pharmaceutical composition including the recombinant protein or a recombinant protein-loaded cancer killer cell is disclosed. Further, disclosed is a method for preparing a recombinant protein-loaded cancer killer cell.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 13, 2022
    Assignee: Gwangju Institute of Science and Technology
    Inventors: Chang-Duk Jun, Bu Nam Jeon, Hey-Ran Kim
  • Patent number: 11440969
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 13, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • Patent number: 11435354
    Abstract: There is provided a simple and minimally invasive adenocarcinoma detection method. The adenocarcinoma detection method of the present invention includes a step of detecting in vitro a presence or absence of an abnormal cleavage in a specific protein in a test subject-derived sample. The abnormal cleavage in the specific protein is, for example, a cleavage resulting in one or more breaks in a peptide bond in the specific protein and/or a cleavage resulting in a deletion of one or two more amino acid residues at one or more sites of the specific protein. The adenocarcinoma detection method of the present invention includes a step of detecting a presence or amount of a protein having the abnormal cleavage or a decrease in an amount of a normal protein.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: September 6, 2022
    Assignees: UNIVERSITY OF MIYAZAKI, OSAKA UNIVERSITY
    Inventors: Masamitsu Nakazato, Nobuhiro Matsumoto, Yasuji Arimura, Hironobu Tsubouchi, Toshifumi Takao, Nobuaki Okumura, Masafumi Fukuda
  • Patent number: 11434301
    Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: September 6, 2022
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens
  • Patent number: 11427648
    Abstract: The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 30, 2022
    Assignees: UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Marcel Blot-Chabaud, Benjamin Guillet, Marie Nollet, Jimmy Stalin, Nathalie Bardin, Françoise Dignat-George
  • Patent number: 11414487
    Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: August 16, 2022
    Assignees: CStone Pharmaceuticals, CStone Pharmaceuticals (Suzhou) Co., Ltd., CStone Pharmaceuticals (Shanghai) Co., Ltd.
    Inventors: Yong Zheng, Jing Li, Gennady Gololobov, Xinhua Zhang, Baotian Yang, Zhewei Tang, Dong Li, Jianqing Xu, Zhuozhi Wang
  • Patent number: 11400133
    Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: August 2, 2022
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
  • Patent number: 11400157
    Abstract: A multiple antigen-binding molecule fusion molecule containing a multiple antigen-binding molecule (?) having an immune cell antigen-binding region and a cancer antigen-binding region, a cancer tissue-specific protease-cleavable linker (?), and a masking molecule (?) containing a polypeptide having the amino acid sequence QDGNE (SEQ ID NO: 15), in which the multiple antigen-binding molecule (?) and the masking molecule (?) are linked via the cancer tissue-specific protease-cleavable linker (?).
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: August 2, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Naoka Hironiwa, Hiroki Kawauchi
  • Patent number: 11400165
    Abstract: The present disclosure provides methods for site-selectively crosslinking payloads to antibodies and other proteins. This can be accomplished using traceless affinity labels designed to label target proteins with bio-orthogonally reactive entities (ORE) using the compositions and methods described herein.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: August 2, 2022
    Assignee: ADVANCED PROTEOME THERAPEUTICS INC.
    Inventors: Alexander Krantz, Andrzej Wilczynski, Grzegorz Rymarczyk
  • Patent number: 11395826
    Abstract: An immunoregulatory agent containing a regulatory agent that regulates Dedicator of cytokinesis 2 (DOCK2)-mediated Rac activation as an active ingredient is provided.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 26, 2022
    Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yoshinori Fukui, Takehito Uruno, Yuki Sugiura
  • Patent number: 11396528
    Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 26, 2022
    Assignee: BGI SHENZHEN
    Inventors: Yunxia Tang, Bo Li, Yong Hou, Shuntao Luo, Ying Huang, Geng Liu, Dongli Li, Xiumei Lin
  • Patent number: 11390685
    Abstract: Provided is binding protein comprising an antigen binding fragment that specifically binds receptor tyrosine-protein kinase ErbB-2 (ErbB2), polynucleotides encoding the binding protein, vectors comprising the polynucleotides, pharmaceutical composition comprising the binding protein as well as methods of using the binding protein. The binding protein can be used for treating a disease or disorder, in which an ErbB2 activity is detrimental or inhibiting growth of ErbB2 positive cells or tumors synergistically with another ErbB2 antibody such as Trastuzumab. The binding protein can also be used for enhancing internalization of an agent or another ErbB2 antibody, for example, Trastuzumab, into ErbB2 positive cells.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: July 19, 2022
    Assignee: BIOSION, INC.
    Inventor: Mingjiu Chen
  • Patent number: 11382965
    Abstract: The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: July 12, 2022
    Assignee: 2seventy bio, Inc.
    Inventors: Richard Morgan, Kevin Friedman
  • Patent number: 11377660
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: July 5, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 11377488
    Abstract: The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: July 5, 2022
    Assignee: CATALENT PHARMA SOLUTIONS, LLC
    Inventor: Gregory T. Bleck
  • Patent number: 11369623
    Abstract: The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 28, 2022
    Assignees: PRISM Pharma Co., Ltd., Eisai R&D Management Co., Ltd.
    Inventors: Takenao Odagami, Hiroyuki Kouji, Yoichi Ozawa, Yusaku Hori
  • Patent number: 11359204
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: June 14, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 11359008
    Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90? and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90? or VKHFSVEGQ in Hsp90?.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: June 14, 2022
    Assignee: University of Southern California
    Inventors: Wei Li, David Woodley, Mei Chen, Divya Sahu, Hangming Dong, Mengchen Zou